Market revenue in 2023 | USD 4,639.6 million |
Market revenue in 2030 | USD 7,538.9 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 27.32% in 2023. Horizon Databook has segmented the North America laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
North America leads the global Laboratory-developed Tests (LDTs) in terms of revenue generation owing to increasing healthcare expenditure, prevalence of chronic diseases, geriatric population, and government funding. Moreover, the outbreak of coronavirus positively impacted the market.
The number of tests increased due to the outbreak of COVID-19 in response to increased demand for quick on-site screening. As a result, several companies are focusing on manufacturing and developing novel tests.
For instance, in September 2022, Allelica launched ancestry-specific Polygenic Risk Score (PRS) analysis as LDT for prostate cancer, coronary artery disease, breast cancer, Alzheimer’s disease, and type 2 diabetes. Furthermore, with the increasing prevalence of cancer and the rapid development of cancer diagnosis, the market is undergoing significant growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America laboratory developed tests market , including forecasts for subscribers. This continent databook contains high-level insights into North America laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account